The Library

Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs

Tools

Rijt, Sabine H. van and Sadler, P. J.. (2009) Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discovery Today, Vol.14 (No.23-24). pp. 1089-1097. ISSN 1359-6446

PDF
WRAP_Sadler_WRAP_PMID_19782150_DrugDisToday.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (608Kb)

Official URL: http://dx.doi.org/10.1016/j.drudis.2009.09.003

Abstract

This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Bioinorganic chemistry, Cancer -- Treatment, Metals in medicine, Antineoplastic agents -- Development, Organometallic compounds
Journal or Publication Title:	Drug Discovery Today
Publisher:	Elsevier Ltd.
ISSN:	1359-6446
Date:	December 2009
Volume:	Vol.14
Number:	No.23-24
Page Range:	pp. 1089-1097
Identification Number:	10.1016/j.drudis.2009.09.003
Status:	Peer Reviewed
Access rights to Published version:	Restricted or Subscription Access
Funder:	Engineering and Physical Sciences Research Council (EPSRC), Medical Research Council (Great Britain) (MRC), European Cooperation in the Field of Scientific and Technical Research (Organization) (COST), European Regional Development Fund (ERDF), Advantage West Midlands (AWM), Birmingham Science City
References:	1 Hambley, T.W. (2007) Metal-Based Therapeutics. Science 318 (5855), 1392- 1393 2 Sadler, P.J. et al. Metals in medicine. (2007) In Biological inorganic chemistry: structure and reactivity (Bertini, I., Gray, H.B., Stiefel, E. I., Selverstone, V. L., Ed.) pp 95-135, University Science Books, U.S.. 3 Sessler, J.L. et al. (2005) Medicinal inorganic chemistry. In ACS Symp. Ser.; 903, (Sessler, J.L., Doctrow, S.R., McMurry, T., Lippard, S.J., Ed.) 453pp, CAPLUS. 4 Storr, T. et al. (2006) Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev. 35 (6), 534-544 5 Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7 (8), 573-584 6 Bergamo, A. and Sava, G. (2007) Ruthenium complexes can target determinants of tumor malignancy. Dalton. Trans. (13), 1267-1272 7 Fricker, S.P. (2007) Metal based drugs: from serendipity to design. Dalton. Trans. (43), 4903-4917 8 Sherman, S.E. et al. (1985) X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2{d(pGpG)}]. Science 230 (4724), 412-417 9 Wang, D. and Lippard, S.J. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 4 (4), 307-320 10 Rademaker-Lakhai, J.M. et al. (2004) A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10 (11), 3717-3727 11 Jakupec, M.A. et al. (2005) KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development- an overview. Int. J. Clin. Pharmacol. Ther. 43 (12), 595-596 12 Clarke, M.J. et al. (1999) Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 99 (9), 2511-2533 13 Aird, R.E. et al. (2002) In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br. J. Cancer 86 (10), 1652-1657 14 Chen, H. et al. (2002) Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J. Am. Chem. Soc. 124 (12), 3064-3082 15 Chen, H. et al. (2003) Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. Proc. Natl. Acad. Sci. U. S. A. 100 (25), 14623-14628 16 Chen, H. et al. (2003) Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J. Am. Chem. Soc. 125 (1), 173-186 17 Wang, F. et al. (2003) Kinetics of aquation and anation of Ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Chem. Eur. J. 9 (23), 5810-5820 18 Hotze, A.C.G. et al. (2004) Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine and 4-methyl-2- phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. J. Biol. Inorg. Chem. 9 (3), 354-364 19 Chen, J.C. et al. (2005) Electronic structures and SARs of the isomeric complexes alpha -, beta -, gamma - [Ru(mazpy)2Cl2] with different antitumor activities. THEOCHEM 728 (1-3), 93-101 20 Hotze Anna, C.G. et al. (2006) Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs. Angew. Chem. Int. Ed. Engl. 45 (29), 4839-4842 21 Peacock, A.F.A. and Sadler, P.J. (2008) Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem. Asian J. 3 (11), 1890-1899 22 van Rijt, S.H. et al. (2009) Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. Inorg. Chem. 48 (4), 1753-1762 23 Peacock, A.F.A. et al. (2006) Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. J. Am. Chem. Soc. 128 (5), 1739-1748 24 Peacock, A.F.A. et al. (2007) Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. J. Am. Chem. Soc. 129 (11), 3348-3357 25 Kostrhunova, H. et al. (2008) DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. J. Med. Chem. 51 (12), 3635-3643 26 Barnard, P.J. and Berners-Price, S.J. (2007) Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev. 251 (13+14), 1889- 1902 27 Powis, G. and Kirkpatrick, D.L. (2007) Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7 (4), 392-397 28 Urig, S. et al. (2006) Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem. Int. Ed. 45 (12), 1881-1886 29 Shaw, C.F., III. (1999) Gold-based therapeutic agents. Chem. Rev. 99 (9), 2589-2600 30 Che, C.-M. et al. (2003) Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem. Commun. (14), 1718-1719 31 Li, C.K.-L. et al. (2006) Anticancer cyclometalated [AuIIIm(C~N~C)mL]n+ compounds: synthesis and cytotoxic properties. Chem. Eur. J. 12 (20), 5253- 5266 32 Gabbiani, C. et al. (2008) Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. Inorg. Chem. 47 (7), 2368-2379 33 Saggioro, D. et al. (2007) Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol. 14 (10), 1128-1139 34 Bindoli, A. et al. (2009) Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 253 (11+12), 1692- 1707 35 Jakupec, M.A. and Keppler, B.K. (2004) Gallium in cancer treatment. Curr. Top. Med. Chem. 4 (15), 1575-1583 36 Meggers, E. et al. (2007) Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. Synlett (8), 1177-1189 37 Smalley Keiran, S.M. et al. (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67 (1), 209-217 38 Bergamo, A. et al. (2008) Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int. J. Oncol. 33 (6), 1281-1289 39 Chatterjee, S. et al. (2008) The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J. Biol. Inorg. Chem. 13 (7), 1149-1155 40 Ott, I. et al. (2008) Alkyne hexacarbonyl dicobalt complexes in medicinal chemistry and drug development. Expert Opin. Ther. Pat. 18 (3), 327-337 41 Ott, I. et al. (2005) Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. J. Med. Chem. 48 (2), 622-629 42 Sergeant, C.D. et al. (2008) Metallo-nucleosides: synthesis and biological evaluation of hexacarbonyl dicobalt 5-alkynyl-2'-deoxyuridines. Org. Biomol. Chem. 6 (1), 73-80 43 Gunatilleke, S.S. et al. (2008) Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. J. Biol. Inorg. Chem. 13 (4), 555-561 44 Oliveira, C.R. et al. (2009) Pre-clinical antitumour evaluation of biphosphinic palladacycle complex in human leukaemia cells. Chem.-Biol. Interact. 177 (3), 181-189 45 Mosi, R. et al. (2006) Rhenium inhibitors of cathepsin B (ReO(SYS)X (Where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of Inhibition. J. Med. Chem. 49 (17), 5262-5272 46 Desoize, B. (2004) Metals and metal compounds in cancer treatment. Anticancer Res. 24 (3A), 1529-1544 47 Kostova, I. (2005) Lanthanides as anticancer agents. Curr. Med. chem. Anticancer Agents 5 (6), 591-602 48 Ott, I. and Gust, R. (2007) Non platinum metal complexes as anti-cancer drugs. Arch. Pharm. 340 (3), 117-126 49 Farrer, N.J. and Sadler, P.J. (2008) Photochemotherapy: targeted activation of metal anticancer complexes. Aust. J. Chem. 61 (9), 669-674 50 Henderson, B.W. et al. (1992) Photodynamic Therapy: Basic Principles and Clinical Applications 51 Detty, M.R. et al. (2004) Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 47 (16), 3897-3915 52 Kostenich, G. et al. (1998) Photosensitization by the near-IR-absorbing photosensitizer lutetium texaphyrin: spectroscopic, in vitro and in vivo studies. J. Porphyrins Phthalocyanines 2 (4-5), 383-390 53 Sharman, W.M. et al. (1999) Photodynamic therapeutics: basic principles and clinical applications. Drug Discovery Today 4 (11), 507-517 54 Cordier, C. et al. (2007) Insertion of a bulky rhodium complex into a DNA cytosine-cytosine mismatch: An NMR solution study. J. Am. Chem. Soc. 129 (40), 12287-12295 55 Junicke, H. et al. (2003) A rhodium(III) complex for high-affinity DNA basepair mismatch recognition. Proc. Natl. Acad. Sci. U. S. A. 100 (7), 3737-3742 56 Ernst, R.J. et al. (2009) DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors. J. Am. Chem. Soc. 131 (6), 2359-2366 57 Choy, H. et al. (2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin. Cancer Res. 14 (6), 1633-1638 58 Hall, M.D. et al. (2007) Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem. 50 (15), 3403-3411 59 Bednarski, P.J. et al. (2006) Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem. Biol. 13 (1), 61-67 60 Mackay, F.S. et al. (2006) A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. Chem. Eur. J. 12 (11), 3155-3161 61 Mackay, F.S. et al. (2007) A potent cytotoxic photoactivated platinum complex. Proc. Natl. Acad. Sci. U. S. A. 104 (52), 20743-20748 62 Vessieres, A. et al. (2005) Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. J. Med. Chem. 48 (12), 3937-3940 63 Hillard, E. et al. (2006) Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. Angew. Chem. Int. Ed. 45 (2), 285-290 64 Nguyen, A. et al. (2009) Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains. Chem. Eur. J. 15 (3), 684-696 65 Failes, T.W. et al. (2007) Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. Chem. Eur. J. 13 (10), 2974-2982 66 Dougan, S.J. et al. (2008) Catalytic organometallic anticancer complexes. Proc. Natl. Acad. Sci. U. S. A. 105 (33), 11628-11633 67 Petzold, H. et al. (2008) Metal and ligand control of sulfenate reactivity: arene ruthenium thiolato-mono-S-oxides. Angew. Chem. Int. Ed. 47 (16), 3008-3011 68 Petzold, H. and Sadler, P.J. (2008) Oxidation induced by the antioxidant glutathione (GSH). Chem. Commun. (37), 4413-4415 69 Barnes, K.R. et al. (2004) Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol. 11 (4), 557- 564 70 Ang, W.H. et al. (2005) Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc. 127 (5), 1382-1383 71 Campone, M. et al. (2007) Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol. 60 (4), 523-533 72 Feazell, R.P. et al. (2007) Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc. 129 (27), 8438-8439 73 Hamelers, I.H.L. et al. (2009) High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin. Cancer Res. 15 (4), 1259-1268 74 Noor, F. et al. (2009) Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells. Chembiochem 10 (3), 493-502
URI:	http://wrap.warwick.ac.uk/id/eprint/3367